What is the recommended preventive and acute management for a 46‑year‑old woman with two migraines per week who has failed prior therapy?

Management of Frequent Migraines with Prior Treatment Failure

This 46-year-old woman with 8 migraines per month clearly meets criteria for preventive therapy and should be started on a beta-blocker (propranolol 80-240 mg/d or metoprolol), valproate (500-1500 mg/d), venlafaxine, or amitriptyline (30-150 mg/d) as first-line preventive treatment, while optimizing her acute therapy with triptans combined with NSAIDs. 1

Preventive Therapy: The Priority

With two migraines weekly (approximately 8 per month), this patient has a clear indication for preventive treatment. The most recent 2025 American College of Physicians guideline establishes that patients with ≥2 days per month of migraine-related disability despite optimized acute treatment warrant preventive therapy 1. The 2021 Nature Reviews guideline similarly recommends preventive treatment for patients adversely affected on ≥2 days per month 2.

First-Line Preventive Options

Start with oral medications before considering newer, more expensive options:

• Beta-blockers: Propranolol (80-240 mg/d) or metoprolol are first-line choices 3, 1
• Valproate: 500-1500 mg/d (contraindicated in women of childbearing potential) 3, 1
• Venlafaxine (SNRI): Effective first-line option 1
• Amitriptyline: 30-150 mg/d 3, 1

The 2025 ACP guideline prioritizes these medications based on comparable efficacy but substantially lower cost compared to CGRP-targeted therapies 1. Each preventive medication requires an adequate trial of 2-3 months before determining efficacy 3.

Second-Line Options After First-Line Failure

If the patient fails to respond to or cannot tolerate first-line oral preventives:

• CGRP antagonist-gepants: Atogepant or rimegepant 1
• CGRP monoclonal antibodies: Eptinezumab, erenumab, fremanezumab, or galcanezumab 1

Critical evidence for treatment-failure populations: The 2026 network meta-analysis specifically examining patients with prior preventive failures found that CGRP-targeted therapies (fremanezumab, eptinezumab, galcanezumab, atogepant, erenumab) reduced monthly migraine days by 2.2-3.4 days compared to placebo, with low to moderate certainty evidence 4. For patients with multiple prior failures, erenumab 140 mg may be preferred over 70 mg 5.

Third-Line Option

Topiramate should only be used after failing both first-line oral preventives AND CGRP-targeted therapies 1. This represents a significant shift from older guidelines due to higher adverse event rates. Topiramate is now formally contraindicated in women of childbearing potential due to neurodevelopmental risks in children exposed in utero 6.

Acute Therapy Optimization

Since the patient has "failed" prior therapy, reassess and optimize acute treatment:

First-Line Acute Treatment

NSAIDs combined with a triptan provide superior efficacy to either alone 7:

• Naproxen 500-550 mg + sumatriptan 50-100 mg, OR
• Ibuprofen 400-800 mg + any triptan
• Aspirin 650-1000 mg + acetaminophen + caffeine combination 8, 3

Treat early in the attack for maximum efficacy 7. If nausea is prominent, add metoclopramide or use a non-oral triptan formulation 3, 8.

Second-Line Acute Treatment (If Triptan + NSAID Fails)

• CGRP antagonist-gepants: Rimegepant, ubrogepant, or zavegepant 7
• Ergot alkaloid: Dihydroergotamine (DHE) 3, 8

Third-Line Acute Treatment

• Lasmiditan (ditan): Only after all other options fail 7

Critical Pitfall: Medication Overuse Headache

Monitor acute medication use closely. Using triptans ≥10 days per month or NSAIDs ≥15 days per month causes medication overuse headache (MOH), which mimics treatment-resistant migraine 7, 9. With 8 migraines monthly, this patient is at high risk. If MOH is present, withdrawal of the overused medication is essential before preventive therapy can work effectively 9.

Avoid opioids and butalbital-containing compounds entirely - they cause dependency, rebound headaches, and treatment failure 8, 7.

Treatment Algorithm

1. Assess for medication overuse - if present, address this first
2. Start first-line preventive: Beta-blocker, valproate (if not childbearing potential), venlafaxine, or amitriptyline
3. Optimize acute therapy: Triptan + NSAID, taken early in attack
4. Trial duration: 2-3 months at therapeutic dose 3
5. If first-line preventive fails: Switch to different first-line agent or advance to CGRP-targeted therapy (gepant or monoclonal antibody)
6. If CGRP therapy fails: Consider topiramate (if not childbearing potential)
7. Monitor monthly migraine days using a headache diary to assess response 3

Special Considerations for This Patient

• Cost matters: The 2025 ACP guideline explicitly prioritizes less expensive oral medications before CGRP-targeted therapies due to cost differences exceeding $10,000 annually 1
• Patient preference: Oral medications are generally preferred over injectables based on patient values 1
• Adherence is crucial: Improvement occurs gradually over weeks to months; patients must understand this to maintain adherence 1
• Childbearing potential: If applicable, avoid valproate and topiramate entirely 6